---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000033"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:18:18.523089+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics annual meeting votes: all director nominees elected, auditor ratified, say-on-pay approved

## Summary
- Elected Class I directors: William F. Bell, Jr., Matthew B. Klein, Stephanie S. Okey, Jerome B. Zeldis; each received >58M votes for.
- Ratified Ernst & Young as independent auditor for FY2023: 69.4M for, 0.4M against, 13.6K abstain.
- Advisory say-on-pay proposal approved: 65.3M for, 1.5M against, 21.7K abstain, 3.0M broker non-votes.
- 74.0M shares outstanding as of record date April 13, 2023.

## SEC filing metadata
- accession: 0001070081-23-000033
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000033/0001070081-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000033/tmb-20230606x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000033
- JSON: https://secwatch.observer/filing/0001070081-23-000033.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000033.txt

## Key facts
- Shareholder Votes
  PTC THERAPEUTICS, INC. shareholders approved Election of four Class I directors at the 2023-06-06 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: The stockholders of the Company elected four Class I directors, each to hold office until the Company's 2026 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows: ​ ​ ​ ​ ​ Director For Withheld Broker Non-Votes William F. Bell, Jr. 63,215,577 3,588,990 2,986,852 Matthew B. Klein, M.D., M.S., F.A.C.S. 66,478,887 325,680 2,986,852 Stephanie S. Okey, M.S. 63,816,731 2,987,836 2,986,852 Jerome B. Zeldis, M.D., Ph.D. 58,377,983 8,426,584 2,986,852
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000033/0001070081-23-000033-index.htm
- Shareholder Votes
  PTC THERAPEUTICS, INC. shareholders approved Non-binding advisory proposal on named executive officer compensation at the 2023-06-06 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: The non-binding advisory proposal on named executive officer compensation was approved by the Company's stockholders with 65,318,123 votes "For,” 1,464,756 votes “Against,” 21,688 votes “Abstained,” and 2,986,852 broker non-votes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000033/0001070081-23-000033-index.htm
- Shareholder Votes
  PTC THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-06 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified by the Company's stockholders with 69,370,823 votes "For,” 406,974 votes “Against,” and 13,622 votes “Abstained.”
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000033/0001070081-23-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.